A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

Key facts

Sponsor

J-Pharma Co., Ltd.

Principal Investigator

Eric K Rowinsky, MD

Uniphar Development, LLC

Intervention

Nanvuranlat(drug)

Enrollment

480 enrolled

Eligibility

18 years · All sexes

Timeline

2026 – 2027

Study locations (18)

• Banner MD Anderson Cancer Center (Site 106), Gilbert, Arizona, United States
• City of Hope (Site 107), Duarte, California, United States
• University of California at Irvine (Site 101), Orange, California, United States
• UCLA Medical Center (Site 117), Santa Monica, California, United States
• Norton Cancer Institute (Site 115), Louisville, Kentucky, United States
• Ochsner Medical Center (Site 120), New Orleans, Louisiana, United States
• Henry Ford Cancer Center (Site 113), Detroit, Michigan, United States
• Karmanos Cancer Center (Site 109), Detroit, Michigan, United States
• Masonic Cancer Center, University of Minnesota (Site 116), Minneapolis, Minnesota, United States
• Rutgers Cancer Institute of New Jersey (Site 103), New Brunswick, New Jersey, United States
• Rosewell Park Comprehensive Cancer Center (Site 114), Buffalo, New York, United States
• Memorial Sloan Kettering Cancer Center (Site 108), New York, New York, United States
• University Hospitals Cleveland Medical Center Seidman Cancer Center (Site 111), Cleveland, Ohio, United States
• James Cancer Hospital and Solove Research Institute (Site 119), Columbus, Ohio, United States
• Mercy Clinic (Site 110), Oklahoma City, Oklahoma, United States
• +3 more locations on ClinicalTrials.gov

Collaborators

Uniphar Development, LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06282575
  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
  Jazz Pharmaceuticals
• RECRUITINGNCT07007832
  Bile Omics for Diagnosing Indeterminate Biliary Strictures
  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• ACTIVE NOT RECRUITINGPHASE1NCT03257761
  Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
  University of Southern California

See all trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract →